Introduction
============

Bladder cancer (BC) is the fifth most prevalent malignancy in both sexes and the 4^th^ in male, the 11^th^ in female, with an expected 81,190 new cases and 17,240 death in the United States, 2018 [@B1]. The incidence rates of BC show imparities in worldwide with the highest morbidity in Europe, Northern America, Western Asia, and Northern Africa, but the lowest morbidity in Eastern, Middle and Western Africa [@B2]. However, the etiology of BC remains unclear. Previous epidemiological studies verified that many risk factors significantly associated with the occurrence of BC, included tobacco smoking, exposure to certain carcinogens like aromatic amines, long-term inflammation stimulation and genetic factors [@B2]-[@B5]. Therein, smoking as an important risk factor, was reported to increase approximately 2-fold to 6-fold risks suffering from BC [@B6]. In the past decades, various researches had been carried out to explore the roles of genetic susceptibility in the occurrence of BC and some susceptible genes were identified, containing tumor protein p53 (TP53) gene [@B7]-[@B10].

TP53 gene (p53 gene), located at 17p13, is extensively regarded as a tumor suppressor gene. As a 53 kDa protein encoded by TP53 gene, p53 had been demonstrated to play an essential role in regulating cell cycle, cell growth, differentiation, proliferation and apoptosis [@B11], [@B12]. Besides, p53 was also involved in maintaining DNA integrality and repairing DNA damage, thus exerting powerful inhibition effect on tumorigenesis [@B13]. As a result, the mutation of the TP53 might result in the loss of function of p53 protein and then induce carcinogenesis [@B14]. Accumulating data have explored the relationship of TP53 polymorphisms with the risk of various cancers. One of these widely studied polymorphisms is a G\>C transition in codon 72 of exon 4, leading to an arginine (Arg) to proline (Pro) amino acidic substitution and generating three different genotypes (Arg/Arg, Pro/Pro and Pro/Arg) [@B15], [@B16].

Various cancers had been demonstrated to be significantly associated with TP53 codon 72 gene polymorphisms, including lung cancer [@B17], nasopharyngeal cancer [@B18], hepatocellular carcinoma [@B19], prostate cancer [@B20], BC [@B21] and so on. Nevertheless, their results remained inconsistent, and the definite role of smoking or tumor status in association with this polymorphism in BC cases was seldom involved. Therefore, we conducted an updated meta-analysis to perform a more precise assessment on the association between this polymorphism and the risk of BC based on all applicable case-control studies.

Materials and Methods
=====================

Literature search strategy
--------------------------

We comprehensively retrieved available papers associated with P53 codon 72 polymorphisms and susceptibility to BC in the online databases PubMed, PMC, EMBASE and Web of Science, published up to May 30th, 2018. The following keywords in combination with Medical Subject Headings (MeSH) terms and text words were utilized: \'p53\' or \'TP53\', \'codon 72\' or \'Arg72pro\' or \'R72P\' or \'rs1042522\' or \'exon 4\', \'polymorphism\' or \'mutation\' or \'variant\', \'bladder cancer\', or \'bladder carcinoma\' or \'bladder tumor\'. In addition, potentially eligible articles were identified via meticulously searching from the reference lists of relevant reviews and original literature.

Inclusion and exclusion criteria
--------------------------------

All eligible articles included in this meta-analysis must meet following criteria: (1) Used a case-control or cohort study design; (2) Evaluated the association between TP53 codon 72 polymorphism and BC risk; (3) Presented sufficient genotype data of both cases and controls to calculate the odds ratios (ORs) and 95% confidence intervals (CIs); (4) Enrolled patients with BC confirmed by histopathological examination and controls with no history of any other malignancies. Besides, the exclusive criteria were in accordance with the follows: (1) No case-control or cohort study; (2) Duplicated or unavailable data; (3) Studies not related to TP53 codon 72 or BC.

Data Extraction
---------------

All available data from the identified studies were extracted respectively by two reviewers (L.Z and Y.W) and then checked by each other. If any disagreement achieved, a third reviewer (ZQ.Q) would join in and reached a consensus. Extracted data were recorded in a predefined form including following items: first author\' name, publication year, ethnicity, source of controls, genotypic method, the number of cases and controls, concrete numbers of Arg/Arg, Arg/Pro and Pro/Pro genotypes and the results of the Hardy-Weinberg equilibrium (HWE) test respectively.

Statistical analysis
--------------------

HWE was assessed in the control groups based on Pearson\'s goodness-of-fit chi-square test (χ^2^ test) and significant equilibrium was considered if the P value was more than 0.05. In addition, pooled ORs with 95% CIs were presented to evaluate the strength of association between TP53 codon 72 polymorphism and susceptibility to BC, by using five different genetic comparison models: allele model (Pro vs. Arg), homozygous model (Pro/Pro vs. Arg/Arg), heterozygous model (Pro/Arg, vs. Arg/Arg) dominant model (Pro/Pro+Pro/Arg vs. Arg/Arg) and recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg). The heterogeneity among these papers was tested by Cochrane Q test and Higgins I^2^ statistic. Accordingly, the fixed effect model (a Mantel-Haenszel method) was applied if the heterogeneity was acceptable (*I^2^* \< 50% or *P*\>0.10) and the random effect model was performed (a DerSimonian-Laird method) if the heterogeneity was unwelcome (*I^2^*\> 50% or *P*\<0.10). Although the random effect model was one way to manage heterogeneity among studies, it could not explain the source of heterogeneity. Hence, subgroup analysis was further utilized to minimize heterogeneity to obtain more credible evidence. Moreover, sensitivity analysis was adopted to determine the stability and reliability of the results by recounting the pooled ORs via consecutively excluding each study once a time. Furthermore, Begg\'s funnel plots and Egger\'s linear regression test were used to check out the publication bias among all studies, and a significantly bias was considered when the *P* value was less than 0.05. STATA 12.0 software (StateCorporation, College Station, TX, USA) was used to conduct statistical analysis.

Results
=======

Studies characteristics
-----------------------

A total of 551 potentially available studies were initially collected from a primary literature retrieval from PubMed, PMC, EMBASE, Web of Science and other sources. Based on above-mentioned inclusion and exclusion criteria, 22 studies were ultimately included in this meta-analysis for further assessment [@B21]-[@B42]. Detailed literature searching and screening steps were shown in **Figure [1](#F1){ref-type="fig"}**. Generally, 3,791 patients with BC and 4,917 controls were involved in this meta-analysis to evaluate the association between TP53 codon 72 polymorphisms and BC risk, as well as the role of tumor status or smoking status in association with this mutation. The population among these studies was comprised of Asian, Caucasians and Africans. Meanwhile, main characteristics of eligible studies were presented in **Table [1](#T1){ref-type="table"}** and **Table [2](#T2){ref-type="table"}**.

Association between TP53 codon 72 polymorphisms and BC risk
-----------------------------------------------------------

Generally, the pooled ORs with 95% CIs were calculated to evaluate the relationship between TP53 codon 72 polymorphisms and the risk of BC, according to five genetic comparison models. The main results of this meta-analysis were detailed in **Table [3](#T3){ref-type="table"}**, containing overall analysis and stratified analysis by ethnicity. The overall analysis showed no remarkable results under five genetic models:*allele model* (OR=1.07, 95% CI=0.95-1.20), *dominant model* (OR=1.08, 95% CI=0.91-1.27),*heterozygous model* (OR=1.06, 95% CI=0.89-1.27), *homozygous model* (OR=1.15, 95% CI=0.91-1.46) and *recessive model* (OR=1.10, 95% CI=0.88-1.36) (**Figure [2](#F2){ref-type="fig"}**). However, significant associations were revealed in Asian group, when stratified by ethnicity: *allele model* (OR=1.19, 95% CI=1.06-1.34), *dominant model* (OR=1.27, 95% CI=1.06-1.52),*homozygous model* (OR=1.36, 95% CI=1.03-1.80). Nevertheless, no positive results were presented in Caucasians. These results indicated that TP53 codon polymorphism was an ethnicity related factor relating to BC susceptibility.

Tumor status associated with TP53 codon 72 polymorphisms in BC cases
--------------------------------------------------------------------

During the process of retrieving eligible articles, we found that a total of 9 studies had described the relationship between TP53 codon 72 genotypes and tumor stage/grade in the case of BC. Hence, we conducted an additional analysis to explore the role of this polymorphism in patients with different tumor stage or grade (**Table [3](#T3){ref-type="table"}**). As a result, no positive finding was shown in the general population. In the relationship between TP53 codon 72 polymorphisms and BC tumor stage in Asian group, positive results were presented in *allele model*: OR=1.68, 95% CI=1.04-2.72; *dominant model*: OR=2.46, 95% CI=1.08-5.61; *heterozygous model*: OR=2.32, 95% CI=1.04-5.14; *homozygote model*: OR=2.66, 95% CI=1.04-6.81 (**Figure [3](#F3){ref-type="fig"}**). However, no association was found between different tumor grade (G3+G4 vs. G1+G2) and this polymorphism (*allele model*: OR=1.16, 95% CI=0.86-1.58; *dominant model* OR=1.29, 95% CI=0.75-2.23; *heterozygous model*: OR=1.25, 95% CI=0.76-2.07; *homozygote model*: OR=1.55, 95% CI=0.70-3.41;*recessive model*: OR=1.25, 95% CI=0.78-1.99) (**Figure [4](#F4){ref-type="fig"}**).

Smoking status associated with TP53 codon 72 polymorphisms in BC cases
----------------------------------------------------------------------

Smoking, as a well-known risk factor of BC susceptibility, was studied among 5 studies to shed light on that whether or not it could lead to the G\>C mutation. Accordingly, an additional analysis was conducted to evaluate the relationship between them. As displayed in **Figure [5](#F5){ref-type="fig"}**, significant associations were displayed between TP53 codon 72 polymorphism and smoking status (allele model: OR=1.40, 95% CI=1.06-1.84; dominant model OR=1.72, 95% CI=1.18-2.50; heterozygous model: OR=1.77, 95% CI=1.19-2.64). The concrete quantitative values were also presented in**Table [3](#T3){ref-type="table"}**.

Sensitivity analysis
--------------------

Sensitivity analysis was conducted to access the stability of results by deleting one single study each time, to reflect the impact of the individual to overall. The sensitivity analysis for the results of TP53 codon 72 genetic polymorphisms and BC risk indicated that no single study significantly influenced the pooled OR and 95% CIs. Namely, our results were robust (**Figure [6](#F6){ref-type="fig"}**).

Publication bias
----------------

The Begg\'s funnel plot and Egger\'s test were applied to assess the publication bias in this meta-analysis. According to the results of them, *P* values were all above 0.05 in all models, indicating no significant bias were identified. In other words, our results were reliable based on the available articles (**Figure [7](#F7){ref-type="fig"}**).

Discussion
==========

Genetic susceptibility has been generally recognized as one of the important risk factors of BC [@B43]. TP53 as a well-known tumor suppressor gene, has been demonstrated to play a vital role in regulating cell growth and maintaining DNA integrity [@B13]. TP53 Codon 72 as a Single Nucleotide Polymorphism (SNP) in exon 4, was found to be able to disturb the normal function of p53 protein in various aspects and induce tumorigenesis [@B44]. Accumulating data had been carried out to explore this polymorphism and BC susceptibility. However, their results remained inconsistent. Although previous meta-analysis had revealed a significant association in Asians [@B10], [@B45], this perspective was lack of persuasion due to limited enrolled studies and deficient genetic comparison model. In addition, the definite role of this polymorphism in different tumor stage or grade of BC had not been fully clarified. What\'s more, as a vital risk factor of BC, whether long-term exposure to cigarette can lead to the G\>C mutation of TP53 codon 72 remained to be defined. Hence, this updated meta-analysis was performed with the larger sample size to evaluate the mutual association between this polymorphism and BC susceptibility and to clarify the above-mentioned doubts.

Our findings verified the relationship between TP53 codon 72 and BC risk in Asians but not Caucasians. It indicated that this polymorphism might be an ethnicity related factor of susceptibility to BC. From another point of view, it seemed that different ethnic groups with multiple genetic backgrounds might have different gene polymorphism risk in the occurrence and development of BC. Sjalander et al. found that the genotype of p53 codon 72 was differentially distributed in different ethnic populations, originating from different regions of the world. The Arg allele was more common among people in northern parts than southern [@B46]. In addition, Shi et al. found that this polymorphism was closely correlated with environmental climate [@B47]. It has been confirmed that the TP53 Pro72 isoform was less active in regulating cellular function than TP53 Arg72 [@B48]. Based on our results, Pro allele was less common in Asians, compared with Arg allele. As a result, we speculated that TP53 Pro 72 could not exert normal tumor suppressor function in Asians, while TP53 Arg72 could maintain the activity.

What\'s more, it was the first time for us to investigate whether or not this polymorphisms was correlated with the tumor status and smoking status in BC cases. Hosen et al. found a difference of TP53 codon 72 genotypes distribution among people with different tumor stage and grade [@B25]. Besides, Kuroda et al. discovered that the Pro72 genotype was more common in ever-smoking population [@B36]. Thus, we decided to explore the definite role of this polymorphism in tumor stage/grade and smoking status.

When it comes to the relationship between TP53 codon 72 genotypes and tumor status in case of BC, Basu et al. proved that the presence of Pro72 could enhance the invasive and metastatic properties of mutant p53 by regulating the reactions with PGC-1α, one important regulator of mitochondrial biogenesis and oxidative phosphorylation [@B49]. Therefore, we retrieved papers and kept an eye on related articles that researched the difference of this polymorphism among BC patients with different tumor stages or grade. Ultimately, 9 articles were found to describe the association of TP53 codon 72 polymorphism with invasive BC (≥pT2) or superficial cancer (\<pT2). Besides, 5 relevant articles compared the different TP53 genotypes distribution between high grade tumor (≥G3) and low grade tumor (G1+G2). Based on our results, patients with invasive bladder cancer (≥pT2) were more likely having the Pro genotype than those with superficial cancer (\<pT2) in Asian groups. Nevertheless, no significant difference was found in this polymorphism among patients with different tumor grade. Therefore, we thought that the Pro in Asians might lead to escalating invasion of BC.

Saikia et al. shed light on that the potential effect of TP53 codon 72 polymorphisms on the risk of cancer via interacting synergistically with environmental factors and lifestyles like alcohol drinking and tobacco smoking [@B50]. Smoking is a defined risk factor of BC, but it was unknown if it could lead to a mutation on TP53 codon 72. Although no specialized study was found focusing on the differential distribution of TP53 codon 72 genotypes in smoking or non-smoking groups, we unexpectedly found that some included studies investigated it in BC cases. Thus, we conducted this extra analysis to explore the potential relationship of smoking status and this polymorphism. As our results shown, there was a significant difference of this polymorphism between smoking or non-smoking groups. Accordingly, we hypothesized that long-term exposure to cigarette could lead to an Arg to Pro transition. Nevertheless, it remained to be established by a more population-based TP53 codon 72 genetic screening.

Recently, a large number of studies have investigated the association between TP53 codon 72 polymorphisms and BC, including mechanism research, cancer susceptibility and prognosis [@B22], [@B44], [@B51]. As reported by Kung, increased growth arrest and decreased apoptosis were found in R72 cells compared with P72 cells. Because this SNP could influence the phosphorylation of p53, the transactivation of the key p53 target (p21), the activation of the kinase AMPK and the change of cell metabolism [@B52]. Finally, the dysfunction of p53 led to elevated risk of carcinogenesis. Except for cancer susceptibility, this polymorphism was also extensively studied as a prognostic factor in various cancers. Zha et al. found that Pro/Pro genotypes correlated with poor prognosis in advanced gastric cancer patients treated with paclitaxel plus capecitabine chemotherapy, while Kumari et al. considered Pro/Pro as a better predictor in the survival of lung cancer patients treated with platinum-based chemotherapy [@B53], [@B54]. Thus, the role of tp53 codon 72 in cancer prognosis remained unclear, and whether or not it could predict the survival of BC needed to be further explored.

To a certain degree, several limitations of this meta-analysis should not be ignored: Firstly, some published studies enrolled in this article did not conform to the HWE, leading to potential bias during genotypic errors or population selection; Secondly, the amount of included studies to explore the relation of TP53 codon 72 polymorphism with tumor stage or grade and smoking status were relatively small. Thus, these results need to be confirmed in more studies with larger sample sizes; Thirdly, adjusted estimates by some other covariances like age and gender could not be conducted in this meta-analysis; Fourthly, included studies all used retrospective study designs and they were less persuasive than perspective studies. Last but not least, BC was a multifactorial disease and persistent interactions between genetic and environmental factors, which might affect the occurrence and progression. The exploration of single gene region could not clarify the association of BC risk comprehensively. Accordingly, more attention should be devoted to interactions of gene-gene and gene-environment in future large multi-centric studies.

Conclusion
==========

In summary, our results shed light on that TP53 codon 72 polymorphism was significantly associated with the susceptibility of BC in Asians, but not in Caucasians. Besides, positive associations were also revealed between this polymorphism and tumor stage/smoking status in BC cases. Based on the positive findings, we hypothesized that long-term exposure to smoking might lead to escalating possibility of a G\>C mutation. Nevertheless, due to aforementioned limits, larger-sample with higher-quality and multi-centric studies were required to clarify these points.

Role of the funding source
==========================

This article was funded by the National Natural Science Foundation of China \[grant number: 81501245; 81871151\].

Author Contributions
====================

NH.S, JD.X: Protocol/project development; XH.M, YM.W, R.C: Data collection or management; ZQ.Q, R.L, CJ.J: Data analysis; L.Z, Y.W: Manuscript writing/editing.

![Flow diagram of the literature selection process.](jcav09p3522g001){#F1}

![Forest plots of association between TP53 codon 72 polymorphisms and bladder cancer risk. (A)allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E)recessive model.](jcav09p3522g002){#F2}

![Forest plots of tumor stage associated with TP53 codon 72 polymorphisms. (A)allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E)recessive model.](jcav09p3522g003){#F3}

![Forest plots of tumor grade associated with TP53 codon 72 polymorphisms. (A)allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E)recessive model.](jcav09p3522g004){#F4}

![Forest plots of smoking status associated with TP53 codon 72 polymorphisms. (A)allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E)recessive model.](jcav09p3522g005){#F5}

![Sensitivity analysis of each included study in dominant model.](jcav09p3522g006){#F6}

![Begg\'s funnel plots of the publication bias in dominant model.](jcav09p3522g007){#F7}

###### 

Main characteristics for the included studies of the association between TP53 codon 72 polymorphisms and bladder cancer

  Year   Author       Ethnicity   SOC   Genotyping   Case   Control   Case (n)   Control(n)   HWE                    
  ------ ------------ ----------- ----- ------------ ------ --------- ---------- ------------ ----- ----- ----- ---- ---------
  2017   Lin          Asian       HB    RT-PCR       46     188       10         23           13    31    100   57   0.246
  2017   Elhawary     Asian       HB    RT-PCR       52     104       14         22           16    28    60    16   0.804
  2017   Avirmed      Asian       HB    PCR          63     79        35         20           8     37    23    19   0.001
  2015   Hosen        Asian       HB    PCR-RFLP     102    140       22         45           35    41    78    21   0.104
  2014   Pineda       Caucasian   HB    TaqMan       1032   1100      588        372          72    628   388   84   0.028
  2013   Lin          Asian       HB    PCR-RFLP     199    140       50         102          47    36    86    18   0.003
  2012   Lin          Asian       PB    PCR-RFLP     94     142       16         55           23    48    68    26   0.824
  2011   Lin          Asian       PB    PCR-RFLP     127    427       27         84           16    125   228   74   0.085
  2011   Eduardo      Caucasian   PB    PCR-RFLP     94     159       64         24           6     90    60    9    0.808
  2011   Srivastava   Asian       HB    PCR-RFLP     200    265       103        93           4     141   106   18   0.749
  2011   Zhang        Asian       HB    PCR-RFLP     120    120       37         59           24    55    47    18   0.141
  2010   Pandith      Asian       HB    PCR-RFLP     108    138       22         68           18    59    53    26   0.030
  2008   Ye           Caucasian   HB    PCR-RFLP     615    598       390        186          39    390   156   52   \<0.000
  2008   Horikawa     Asian       HB    PCR-CTPP     227    267       73         118          36    93    136   38   0.297
  2008   Chung        Asian       HB    PCR-RFLP     170    402       47         87           36    134   194   74   0.797
  2003   Kuroda       Asian       HB    PCR-RFLP     112    175       38         38           36    63    77    35   0.200
  2003   Mabrouk      Africa      PB    PCR          47     34        21         23           3     13    19    2    0.254
  2002   Soulitzis    Caucasian   PB    PCR          50     99        30         18           2     24    64    11   0.002
  2001   Toruner      Caucasian   PB    PCR          121    114       43         57           21    42    55    17   0.884
  2000   Brio         Caucasian   PB    PCR-RFLP     50     145       28         18           4     71    54    20   0.071
  2000   Chen         Asian       HB    PCR          58     59        26         25           7     25    26    8    0.765
  1995   Wu           Asian       HB    PCR-RFLP     151    56        69         60           22    26    24    6    0.896

SOC: Source of controls; PB: Population-based controls; HB: Hospital-based controls; AA: ArgArg; AP: ArgPro; PP:ProPro; HWE: Hardy-Weinberg equilibrium.

###### 

Main characteristics of individual studies to explore the role of smoking or tumor status associated with TP53 codon 72 polymorphisms in bladder cancer

  ------------- ----------- ---------------------------- ---------------- ------------- ---- ---- ---- ----
  Tumor stage               Superficial pTis, pTa, pT1   Invasive ≥ pT2                                
  Year          Surname     Ethnicity                    AA               AP            PP   AA   AP   PP
  2015          Hosen       Asian                        15               34            26   7    11   9
  2011          Eduardo     Caucasian                    38               15            5    26   9    1
  2011          Zhang       Asian                        33               39            13   4    20   11
  2010          Pandith     Asian                        16               26            7    6    43   10
  2008          Horikawa    Asian                        59               91            26   14   27   10
  2002          Soulitzis   Caucasian                    26               16            2    4    2    0
  2001          Toruner     Caucasian                    30               45            13   13   12   8
  2000          Chen        Asian                        24               9             1    2    16   6
  1995          Wu          Asian                        36               29            10   28   25   8
  Tumor grade               G1 + G2                      ≥G3                                           
  Year          Surname     Ethnicity                    AA               AP            PP   AA   AP   PP
  2015          Hosen       Asian                        16               26            22   6    19   13
  2010          Pandith     Asian                        17               32            3    6    40   10
  2008          Horikawa    Asian                        38               66            16   35   52   20
  2002          Soulitzis   Caucasian                    23               14            2    7    4    0
  1995          Wu          Asian                        38               33            13   26   21   6
                                                         Smoking          Non-smoking                  
  Year          Surname     Ethnicity                    AA               AP            PP   AA   AP   PP
  2010          Pandith     Asian                        16               58            16   6    10   2
  2003          Kuroda      Asian                        29               32            32   9    6    4
  2001          Toruner     Caucasian                    25               38            17   12   15   4
  1995          Wu          Asian                        31               36            8    28   18   10
  ------------- ----------- ---------------------------- ---------------- ------------- ---- ---- ---- ----

###### 

Meta-analysis results of individual studies included in this meta-analysis

  Variables               No. of studies   Allele model      Dominant model   Heterozygous model   Homozygous model   Recessive model                                                                                                           
  ----------------------- ---------------- ----------------- ---------------- -------------------- ------------------ ----------------- ------- ----------------- ------- ------- ------------------ ------- ------- ------------------ ------- -------
  Total                   22               1.07(0.95,1.20)   0.000            58.4%                1.08(0.91,1.27)    0.000             62%     1.06(0.89,1.27)   0.000   62.2%   1.15(0.91,1.46)    0.002   53.2%   1.10(0.88,1.36)    0.001   54.3%
  Ethnicity                                                                                                                                                                                                                                     
  Asian                   15               1.19(1.06,1.34)   0.057            39.7%                1.27(1.06,1.52)    0.042             42.4%   1.23(0.99,1.51)   0.013   50.3%   1.36(1.03,1.80)    0.021   47.6%   1.21(0.92,1.59)    0.002   59.1%
  Caucasian               6                0.84(0.68,1.04)   0.012            67.5%                0.78(0.56,1.07)    0.001             76.1%   0.79(0.56,1.12)   0.001   76.3%   0.81(0.59,1.11)    0.240   25.9%   0.84(0.67,1.06)    0.544   0.0%
  Africa                  1                0.87(0.45,1.70)   \-               \-                   0.77(0.31,1.88)                              0.75(0.30,1.88)   \-      \-      0.93(0.14,6.32)    \-      \-      1.09(0.17,6.91)    \-      \-
  Tumor stage                                                                                                                                                                                                                                   
  ≥pT2 vs \<pT2           9                1.39(0.94,2.05)   0.001            70.1%                1.66(0.90, 3.08)   0.000             71.7%   1.60(0.87,2.94)   0.002   67.6%   1.94(0.93,4.05)    0.013   58.8%   1.43(0.98,2.10)    0.396   4.7%
  Ethnicity                                                                                                                                                                                                                                     
  Asian                   6                1.68(1.04,2.71)   0.001            76.5%                2.46(1.08,5.61)    0.000             77.5%   2.32(1.04,5.14)   0.002   73.4%   2.66(1.04,6.81)    0.006   69.4%   1.46(0.92,2.33)    0.287   19.3%
  Caucasian               3                0.89(0.57,1.39)   0.556            0.00%                0.76(0.43,1.36)    0.980             0.0%    0.74(0.40,1.37)   0.867   0.0%    1.05(0.41,2.68)    0.452   0.0%    1.28(0.48,3.39)    0.337   8.0%
  Tumor grade                                                                                                                                                                                                                                   
  ≥G3 vs G1+G2            5                1.16(0.86,1.58)   0.195            33.9%                1.29(0.75, 2.23)   0.100             48.6%   1.25(0.76,2.07)   0.184   35.6%   1.55(0.70,3.41)    0.110   47.0%   1.25(0.78,1.99)    0.379   4.9%
  Ethnicity                                                                                                                                                                                                                                     
  Asian                   4                1.20(0.86,1.68)   0.139            45.4%                1.40(0.75,2.62)    0.057             60.0%   1.33(0.73,2.41)   0.106   51.0%   1.66(0.69,3.96)    0.064   58.7%   1.27(0.74,2.19)    0.258   25.7%
  Caucasian               1                0.74(0.22,2.47)   \-               \-                   0.82(0.21,3.28)    \-                \-      0.94(0.23,3.79)   \-      \-      0.63(0.03,14.56)   \-      \-      0.65(0.03,14.58)   \-      \-
  Smoking status                                                                                                                                                                                                                                
  No-smoking vs smoking   5                1.40(1.06,1.84)   0.706            0.0%                 1.72(1.18,2.50)    0.897             0.0%    1.77(1.19,2.64)   0.909   0.0%    1.53(0.83,2.79)    0.501   0.0%    1.21(0.70,2.11)    0.425   0.0%
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